Zydus Cadila Opens New Fronts In COVID-19 Battle
COVID-19 DNA Vaccine Phase III Data By April
Executive Summary
With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. While Phase III data for its DNA vaccine candidate is expected by April, the latest to join the pack is ZYIL1, a novel oral small molecule NLRP3 inhibitor.
You may also be interested in...
Pre-Launch Demand Outstrips Supply For Zydus COVID-19 Vaccine
Zydus Cadila expects to launch its DNA COVID-19 vaccine in the first quarter of fiscal 2022 but it already has more advance purchase orders than it can produce. Meanwhile, the Indian firm is confident of saroglitazar being approved for primary biliary cholangitis in the US, with the NCE also poised to become the largest contributor to India sales in three to five years.
Zydus Cadila Testing Three-Dose COVID-19 Vaccine
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
Need a specific report? 1000+ reports available
Buy Reports